Verdiva Bio Company Profile, Contacts & Intelligence

Verdiva Bio Overview

Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Our most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated best-in-class efficacy potential in a phase 1 study in Australia, which also confirmed the viability of once-weekly dosing. We are also developing a portfolio of amylin molecules, including oral and subcutaneous agonists, and other undisclosed programs that offer the potential for enhanced efficacy, improved tolerability, and healthier weight loss. The Verdiva team will harness the emerging science in gut-brain biology and leverage their history of successful drug development to advance novel therapeutic options aiming to transform the lives of millions living with obesity worldwide. For more information, please visit www.verdivabio.com.

Headquarters

London, City of, United Kingdom

Website

verdivabio.com

Industry

Biotechnology Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology)

Verdiva Bio Contact Intelligence

See which contact channels and departments are represented in the visible AeroLeads data.

Verdiva Bio People & Org Chart Preview

Sample people records show job titles and whether email or phone data is available without exposing raw contact details.

Compare Similar Companies to Verdiva Bio

Explore companies in related markets and compare their industry and employee estimates.